News and Updates

FDA leadership is scrutinizing unexplained price markups on medical consumables, signaling a potential shift toward greater supply chain transparency.

Coya Therapeutics hits a major milestone as the 100th patient joins the ALSTARS trial for COYA 302, a promising new approach to treating ALS.

New trial data shows ivonescimab significantly improves overall survival in EGFR-mutated NSCLC patients, offering a potential breakthrough in lung cancer.

BH-30643 shows a 45% response rate in osimertinib-resistant NSCLC patients. Discover how this new targeted therapy is breaking down cancer drug resistance.

Roche’s Phase III trial finds the Lunsumio combination meets primary endpoints for follicular lymphoma, offering new hope for durable cancer treatment.

The DOLF project enters its final trial stage in Liberia, testing a triple-drug regimen to accelerate the global eradication of river blindness.

Arrowhead Pharmaceuticals reveals promising clinical trial results for its RNAi therapy treating mixed hyperlipidaemia. Discover the potential impact here.

Avacta confirms clinical proof of mechanism for AVA6000, a groundbreaking pro-drug designed to reduce chemotherapy side effects using FAP-targeted therapy.

Arch Biopartners sees shares dip amid market scrutiny. Discover how clinical trial progress and fiscal runway are impacting the firm's biotech outlook.

The University of Miami launches ResearchPass to simplify clinical trial discovery, boosting patient access and accelerating medical research outcomes.